Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses recent updates with the use of interferon in patients with low- and high-risk polycythemia vera (PV), which he presented at this year's IACH meeting. Prof. Kiladjian shares insights into the efficacy of ropeginterferon alfa-2b in this patient population, referencing findings from the PROUD-PV, CONTINUATION-PV, and Low-PV studies (NCT01949805; NCT02218047; NCT03003325). This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
